This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Cell & Gene Therapy Manufacturing & Commercialization Europe
Save the Date: 2-5 December 2024
Convention Centre DublinDublin, Ireland

Christopher Bravery, Ph.D.
Consulting Regulatory Scientist at Advbiols
Speaker

Profile

Christopher founded Consulting on Advanced Biologicals Ltd at the end of 2009 in order to support those developing ATMP and other novel biological medicines. Advbiols focuses on the application of regulatory science to preclinical and quality, along with European regulatory strategy. In addition to providing consulting services, Christopher also runs workshops on various topics. Christopher has a PhD in xenotransplantation immunology and spent 8 years in biotech (Imutran Ltd, A Novartis Pharma AG Co. and Intercytex) before joining the MHRA as a quality (CMC) assessor (biologicals and biotechnology unit). During this time Christopher was involved with National implementation of the new Advanced Therapies Regulation and also involved through his participation in the CHMP’s cell products working party (CPWP) in implementation at the EMA level including drafting guidelines.

Agenda Sessions

  • Potency Assays - Latest Development and Validation Strategies for Gene Therapy Products

    15:40
  • Comparability for Cell and Gene Products

    09:00
  • Comparability for Cell and Gene Products

    11:00
  • Comparability for Cell and Gene Products

    13:30
  • Comparability for Cell and Gene Products

    15:30